Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Notes Payables (2021)

Coherus Oncology (CHRS) has disclosed Notes Payables for 2 consecutive years, with $81.0 million as the latest value for Q3 2021.

  • Quarterly Notes Payables changed N/A to $81.0 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $81.0 million through Sep 2021, changed N/A year-over-year, with the annual reading at $1.1 million for FY2013, N/A changed from the prior year.
  • Notes Payables hit $81.0 million in Q3 2021 for Coherus Oncology, roughly flat from $80.6 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $81.0 million in Q3 2021 to a low of $80.2 million in Q1 2021.